Compass Pathways (CMPS) to Release Quarterly Earnings on Thursday

Compass Pathways (NASDAQ:CMPS) is expected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:00 AM ET.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Tuesday, March 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.59). On average, analysts expect Compass Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Compass Pathways Price Performance

Shares of CMPS traded up $0.16 during trading hours on Wednesday, reaching $9.48. 619,150 shares of the company’s stock traded hands, compared to its average volume of 3,509,836. The stock has a market cap of $1.22 billion, a PE ratio of -3.06 and a beta of 2.39. The company has a current ratio of 0.77, a quick ratio of 0.77 and a debt-to-equity ratio of 0.55. The firm’s 50 day simple moving average is $6.80 and its 200-day simple moving average is $6.54. Compass Pathways has a 12 month low of $2.25 and a 12 month high of $10.21.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CMPS. Morgan Stanley dropped their price target on Compass Pathways from $18.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday, March 25th. B. Riley Financial began coverage on Compass Pathways in a research report on Friday, April 24th. They set a “buy” rating and a $17.00 price target for the company. BTIG Research reiterated a “buy” rating and set a $14.00 price target on shares of Compass Pathways in a research report on Monday, April 20th. Royal Bank Of Canada lifted their price target on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Finally, Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.45.

Hedge Funds Weigh In On Compass Pathways

Large investors have recently bought and sold shares of the stock. Persistent Asset Partners Ltd purchased a new position in Compass Pathways in the 4th quarter worth approximately $38,000. Advisory Services Network LLC purchased a new position in Compass Pathways in the 3rd quarter worth approximately $41,000. MML Investors Services LLC purchased a new position in Compass Pathways in the 4th quarter worth approximately $69,000. Magnetar Financial LLC purchased a new position in Compass Pathways in the 4th quarter worth approximately $91,000. Finally, Raymond James Financial Inc. increased its stake in Compass Pathways by 82.7% in the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after purchasing an additional 6,228 shares during the period. 46.19% of the stock is owned by hedge funds and other institutional investors.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.